Intelligent Bio Solutions Advances Non-Invasive Drug Testing Technology with FDA Clearance Bid
TL;DR
INBS poised for 2025 U.S. launch with non-invasive drug screening system, offering potential first-mover advantage in diverse industries.
INBS preparing for U.S. launch with FDA 510(k) submission, showing 94.1% accuracy in detecting opiates via fingerprint sweat.
INBS' non-invasive drug screening system contributes to a safer environment by enabling rapid and accurate detection of recent drug use.
INBS's Intelligent Fingerprinting Drug Screening System gaining global traction for its innovative approach to combating drug use.
Found this article helpful?
Share it with your network and spread the knowledge!
Intelligent Bio Solutions is progressing toward U.S. market entry with its innovative Intelligent Fingerprinting Drug Screening System, targeting a 2025 launch after submitting a 510(k) premarket notification to the FDA. The device represents a significant advancement in drug testing technology, offering a non-invasive method of detecting recent drug use through fingerprint sweat analysis.
The company's validation studies demonstrate impressive accuracy, with 94.1% effectiveness in detecting opiates. This technological breakthrough could revolutionize drug screening across multiple sectors, including logistics, mining, retail, and marine operations. Currently, Intelligent Bio Solutions has established a robust global presence, operating in 24 countries with over 450 commercial accounts.
The FDA's classification of the system as a Class II medical device underscores its potential medical and safety applications. By providing a quick, portable, and accurate drug screening method, the technology addresses critical workplace safety concerns and offers a less intrusive alternative to traditional drug testing approaches.
As the company expands its distributor network and prepares for U.S. market entry, the Intelligent Fingerprinting Drug Screening System represents a potentially transformative solution for organizations seeking efficient and reliable drug detection methods. The technology's non-invasive nature and high accuracy rate position it as a promising innovation in workplace and safety-critical environment screening.
Curated from InvestorBrandNetwork (IBN)
